Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Cosmo Pharmaceuticals N.V.    COPN   NL0011832936


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Cosmo Pharmaceuticals N : announces worldwide exclusive Distribution Agreement for Eleview with Medtronic

share with twitter share with LinkedIn share with facebook
share via e-mail
12/02/2019 | 10:22am EST

Dublin - Cosmo Pharmaceuticals NV (SIX: COPN) announced today that it has entered into a new worldwide supply and distribution agreement for Eleview with Medtronic (with the exception of Japan and Canada, licensed respectively to EA Pharma and Pendopharm), having in the meantime terminated by mutual consent the co-marketing agreement with Fujifilm.

'This deal further strengthens our cooperation with Medtronic and allows the Eleview franchise to expand on a global scale. We are looking forward to making Eleview a worldwide success', said Alessandro Della Cha, CEO of Cosmo.

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders and Endoscopy. The Company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, Colonic Infections and detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of its novel Artificial Intelligence device to be used in coloscopies and GI procedures. Further, Cosmo is the licensee for US of the novel agent for procedural sedation, Remimazolam.


Tel: +353 1 817 03 70

Email: ndonnelly@cosmopharma.com

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.

This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.

The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.

This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.

This press release does not constitute an 'offer of securities to the public' within the meaning of Directive 2003/71/EC of the European Union (the 'Prospectus Directive') of the securities referred to in it (the 'Securities') in any member state of the European Economic Area (the 'EEA'). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
01/22COSMO PHARMACEUTICALS N : Methylene Blue MMX regulatory update Substantial align..
01/21COSMO PHARMACEUTICALS METHYLENE BLUE : Substantial alignment reached with FDA on..
01/13Acacia Pharma enters into strategic in-licensing, investment and loan transac..
01/13Cosmo sub-licenses its ByFavo US rights to Acacia Pharma, takes an initial 14..
01/10Boeing faces fresh scandal
01/10Cosmo sub-licenses its ByFavo™ (Remimazolam) US rights to Acacia Pharma..
2019RedHill Biopharma Initiates U.S. Promotion of Aemcolo for Travelers' Diarrhea
2019COSMO PHARMACEUTICALS N : announces worldwide exclusive Distribution Agreement f..
2019Cosmo Pharmaceuticals announces worldwide exclusive Distribution Agreement fo..
2019COSMO PHARMACEUTICALS N : appoints New CSO; as current CSO retires
More news
Financials (EUR)
Sales 2019 47,1 M
EBIT 2019 -17,4 M
Net income 2019 -27,6 M
Finance 2019 119 M
Yield 2019 -
P/E ratio 2019 -40,5x
P/E ratio 2020 -83,1x
EV / Sales2019 20,6x
EV / Sales2020 12,0x
Capitalization 1 090 M
Duration : Period :
Cosmo Pharmaceuticals N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COSMO PHARMACEUTICALS N.V.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 4
Average target price 99,52  €
Last Close Price 74,53  €
Spread / Highest target 73,7%
Spread / Average Target 33,5%
Spread / Lowest Target -4,98%
EPS Revisions
Alessandro E. Della Chà Chief Executive Officer & Executive Director
Mauro Severino Ajani Executive Chairman
Giuseppe Cipriano Chief Operating Officer
Niall Donnelly Chief Financial Officer & Head-Investor Relations
Davide Malavasi Director-Qualified Person & Technical
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.68%390 359
ROCHE HOLDING AG4.27%284 454
PFIZER1.63%220 369
MERCK AND COMPANY-5.46%218 904
NOVARTIS-0.09%213 484